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SUSCEPTIBILITY OF CLINICAL ISOLATES OF Bacteroides fragilis GROUP STRAINS TO CEFOXITIN,
CEFOPERAZONE AND TICARCILLIN/CLAVULANATE
Arnaldo Aires PEIXOTO JÚNIOR(1),  Márcia Maria de Negreiros P. ROCHA(2), José Luciano Bezerra MOREIRA(2) &  Cibele Barreto Mano de CARVALHO(2)
SUMMARY
A total of 40 strains of the B. fragilis group was isolated from clinical specimens in two hospital centers in Fortaleza from 1993
to 1997. The most frequently isolated species was Bacteroides fragilis (19 strains) and most isolates came from intra-abdominal and
wound infections. The susceptibility profile was traced for cefoxitin, cefoperazone and ticarcillin-clavulanate by using the agar
dilution reference method. All isolates were susceptible to ticarcillin-clavulanate (128/2µg/ml). Resistance rates of 15 and 70% were
detected to cefoxitin (64µg/ml) and cefoperazone (64µg/ml), respectively. Such regional results permit a better orientation in choosing
this group of antibiotics for prophylaxis and therapy especially in relation to cefoxitin, which is frequently used in the hospital centers
studied.
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INTRODUCTION
β-lactam antibiotics are critical agents in the treatment of anaerobic
infections. Research from the 1970s showed that most anaerobes
including the Bacteroides  fragilis group and other  Bacteroides strains
were susceptible to penicillin G, ampicillin and amoxicillin13. From the
1980s on, resistance to penicillin started to be detected especially among
Fusobacterium  and Clostridium strains10.
The Bacteroides fragilis group are the most frequently anaerobic
bacteria isolated from human infections and the most resistant to beta-
lactam antibiotics. More than 90% are resistant to penicillin G and
derivatives. Inside the group of cephalosporins, the most active are
cefoxitin, cefotetan and ceftizoxime. The third generation cephalosporins,
cefotaxime, cefoperazone and ceftriaxone present more activity than those
of first generation to this bacterial group but high proportions of resistance
varying between 30 and 60% have been found. The monobactam
aztreonam has poor activity against anaerobes and is not indicated in the
treatment of anaerobic infections. Carbapenens (imipenem and
meropenem) and combinations of a β-lactam drug plus a β-lactamase
inhibitor show, at present, the best activity against the  B. fragilis group10.
Considering the great importance of the B. fragilis group, as well as
the large use of the β-lactam antibiotics in human infections, the present
study had as purposes, to determine the B. fragilis group susceptibility
profiles to cefoxitin, cefoperazone and ticarcillin-clavulanate.
MATERIAL AND METHODS
I. Bacterial strains
A total of 40 strains were isolated from non-duplicate clinically
significant isolates collected from 1993 to 1997 at two hospitals in
Fortaleza/CE (Hospital Universitário Walter Cantídio -14 strains- and
Instituto Dr. José Frota -26 strains). The anaerobes tested were B. fragilis
group species as follows: B. fragilis (19), B. distasonis (6), B. ovatus
(4), B. caccae (4), B. thetaiotaomicron (3), B. uniformis (2), B. vulgatus
(1) and Bacteroides sp (1). Most isolates came from intra-abdominal
and wound infections and more than half of the isolates were from surgical
ward patients (Table 1). The specimens were plated onto Bacteroides
Bile Esculin agar and phenylethyl alcohol agar (supplemented with 5%
defibrinated sheep blood and menadione 10µg/ml). They were incubated
at 37 oC for 48h in anaerobic jars. The anaerobic environment was
obtained using commercially available gas generator  envelope for
anaerobiosis (DIFCO). Suspect organisms were transferred to Brain Heart
Infusion broth (DIFCO) (supplemented with hemin solution 5µg/ml and
menadione 10µg/ml) and were identified by established methodology13.
The strains were maintained at –15 oC in BHIs medium with 20%
glycerol until the susceptibility tests could be done.
II. Antimicrobial susceptibility testing
All the strains were tested for susceptibility to cefoxitin (Merck Sharp
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& Dhome, Rahway, NJ), cefoperazone (Sigma Chemical CO, St Louis,
MO) and ticarcillin-clavulanate (SmithKline Beecham). Antimicrobial
susceptibility tests were performed by the agar dilution method as
standardized by the National Committee for Clinical Laboratory
Standards (NCCLS) using Wilkins-Chalgren agar11. The agar dilution
tests plates were inoculated with a Steers replicator and all the procedures
followed the recommendation of the NCCLS manual. Reference strains
of B. fragilis (ATCC 25285) and B. thetaiotaomicron (ATCC 29741)
were included in each experiment to assess the reliability of the method.
Resistance was defined as follows: MIC ≥ 64µg/ml for cefoperazone;
MIC ≥ 64µg/ml for cefoxitin and MIC ≥ 128/2 for ticarcillin-clavulanate.
RESULTS
40 strains from the Bacteroides fragilis group were isolated. Most
of the species were B. fragilis, with a total of 19 samples. The sources of
the specimens from where the B. fragilis group organisms were isolated
are detailed in Table 1.
From the tested antibiotics and combinations, ticarcillin-clavulanate
was the most effective. All the strains were susceptible to this association
with a CIM50 of 4 µg/ml and CIM90 of 32 µg/ml. Cefoxitin showed
relatively good activity with a moderate resistance rate of 15% (Table 2)
for the tested strains; a MIC50 of 16 µg/ml and a MIC90 of 64 µg/ml
were observed for this antibiotic. Cefoperazone did not show any
satisfactory activity against the tested microorganisms. A 70% resistance
to this drug (Table 2) and a MIC50 of 64 µg/ml and a MIC90 >256 µg/
ml were observed.
From the strains of the Bacteroides fragilis group isolated, the B.
fragilis species was more susceptible to β-lactam antibiotics than
Bacteroides non-fragilis strains (Table 2).
DISCUSSION
The discovery of the antibiotics, the rising of vaccines, the recognition
of the importance of feeding and sanitary education as promoters of
health and human expectancy as well as the advances in microbiology,
concerning the techniques of isolation and bacterial identification,
provided a change of agents involved in human infections, from classical
pathogens of exogena origin to opportunist pathogens, components of
normal human microbiota8.
Anaerobic bacteria are the predominant microorganisms in many
human anatomic sites thus, taking part in numerous processes as
opportunists. The B. fragilis group, the Gram negative pigmented bacilli,
F. nucleatum, C. perfringens, C. ramosum and Peptostreptococcus
gathered as a whole, are responsible for half to 2/3 of the clinically
significant isolates of anaerobic bacteria. The B. fragilis group is the
most frequent isolate from infectious processes and within this group,
B. fragilis and B. thetaiotaomicron are the ones with major clinical
implications13.
Among the three β-lactam drugs tested in this study, the association
ticarcillin-clavulanate was the most active agent against the B. fragilis
group organisms. Ticarcillin-clavulanate resistance has been reported,
and between 1988 and 1998, in the USA, France and Canada, a low
resistance rate was observed, ranging from 0.2 to 1.7% 2,4,5,12.
The resistance to cephalosporins, especially to cefoxitin, the most
active in the group against the B. fragilis group has varied among the
species tested and hospitals studied. However, it is important to remember
that the methodology and the choice for critical concentration, as well
as, the selection of tested species are important determinants of this
variability. In the hospitals researched, cefoxitin is one of the antibiotics
chosen for the treatment of anaerobic infections, especially in surgical
wards from where most of the clinical specimens were sent. Resistance
rate of 15% to cefoxitin was detected. In the last two decades, in the
USA, France, Canada, New Zealand, Spain, Italy and Brazil, rates of
resistance to cefoxitin that varied between 1 and 26% were reported1,2,3,4,5,6,
9,12
.
Third generation cephalosporins, as cefoperazone, are not chosen in
empirical therapy of infections by the Bacteroides fragilis group because
Table 1
Sources of specimens from which B. fragilis group species were isolated
SOURCE  ISOLATES No.       %
Intra-abdominal infections 17 42.5
Infected wounds 7 17.5
Soft tissue infection 5 12.5
Chronic otitis media 5 12.5
Blood 1 2.5




Resistance rates of B. fragilis group species
Antimicrobial (breakpoint)  B. fragilis group B. fragilis Bacteroides non-fragilis*
(n=40) (n=19) (N=21)
Cefoxitin ( 64µg/ml ) 6 (15%) 0 6 (28%)
Cefoperazone ( 64µg/ml ) 28 (70%) 11 (58%) 17 (81%)
ticarcillin/ clavulanate  ( 128/2µg/ml ) 0 0 0
*B. thetaiotaomicron, B. distasonis, B. ovatus, B. uniformis, B. caccae , B. vulgatus and Bacteroides sp.
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of high risk of resistance. In our study, a percentage of 70% of resistance
to this antimicrobial was found.
It has been reported that B. fragilis species is the most susceptible to
most β-lactam antibiotics, while the rate of resistance is considerably
higher among the other species of this group. It has also been reported
that most of the resistant strains belong to the B. thetaiotaomicron, B.
ovatus and B. distasonis species and are producers of β-lactamases. It is
well known that Bacteroides fragilis and related species produce several
kinds of beta-lactamases such as oxyiminocephalosporinase,
penicillinase, and metallo-beta-lactamase. In relation to the beta-lactams
tested in this study and the percentage of resistance among the various
species of the B. fragilis group, other studies of in vitro activities of
beta-lactams for Bacteroides fragilis group are similar to those reported
here.
FINEGOLD et al.7 have pointed out chloramphenicol, imipenem,
combination of beta-lactam drugs and beta-lactamase inhibitors and
metronidazole as drugs of choice for the B. fragilis group infections
therapy. They suggest that drugs with lesser activity, as cefoxitin and
clindamycin, may be very useful in patients who are not seriously ill or
in situations where susceptibility to these agents can be demonstrated in
vitro.
We conclude from our study that:
• The level of resistance to cefoxitin may reflect the use of this drug
in the centers studied since this antimicrobial is not routinely
administrated to outpatients.
• Periodic studies of the Bacteroides fragilis group resistance are
essential in order to evaluate the susceptibility patterns which might
influence the choice of empirical therapy.
RESUMO
Sensibilidade à cefoxitina, cefoperazona e ticarcilina-ácido
clavulânico de cepas do grupo Bacteroides fragilis isoladas de
espécimes clínicos
Um total de 40 cepas do grupo B. fragilis foi isolada de espécimes
clínicos em dois centros hospitalares de Fortaleza no período de 1993 a
1997. A espécie mais frequentemente isolada foi Bacteroides fragilis
(19 cepas) tendo a maioria dos microrganismos sido isolada de infecção
intra-abdominal e ferida cirúrgica infectada. Foi traçado o perfil de
sensibilidade à cefoxitina, cefoperazona e associação ticarcilina-ácido
clavulânico, utilizando-se o método de referência de diluição em ágar.
Todas as espécies testadas apresentaram sensibilidade à ticarcilina-ácido
clavulânico (128/2µg/ml). Percentuais de resistência de 15 e 70% foram
detectados para cefoxitina (64µg/ml) e cefoperazona (64µg/ml)
respectivamente. A espécie B. fragilis apresentou os menores percentuais
de resistência quando comparada com as demais espécies do grupo. Estes
resultados regionais permitem uma melhor orientação na escolha deste
grupo de antibióticos, para profilaxia ou terapêutica, principalmente com
relação à cefoxitina que é frequentemente empregada nos centros
hospitalares estudados.
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